US Spina Bifida Market

ID: MRFR/MED/15162-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Spina Bifida Market Research Report By Type (occulta, closed neural tube defects, meningocele, myelomeningocele), By Diagnosis (blood tests, ultrasound, amniocentesis, others, maternal serum alpha-fetoprotein (MSAFP) test, test to confirm high AFP levels, other blood tests), By Treatment (medical procedure, surgery, oral medications, others, urinary catheterization, urinary diversion, enema, spine surgery, fetal endoscopic surgery, spinal fusion, suprapubic cystostomy, caesarean section, antibiotics) and By End User (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Type of Spina Bifida (USD Million)
      1. 4.1.1 Spina Bifida Occulta
      2. 4.1.2 Meningocele
      3. 4.1.3 Myelomeningocele
    2. 4.2 Construction, BY Treatment Type (USD Million)
      1. 4.2.1 Surgical Intervention
      2. 4.2.2 Medication
      3. 4.2.3 Physical Therapy
      4. 4.2.4 Occupational Therapy
    3. 4.3 Construction, BY Patient Age Group (USD Million)
      1. 4.3.1 Pediatric
      2. 4.3.2 Adult
      3. 4.3.3 Geriatric
    4. 4.4 Construction, BY Healthcare Setting (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Outpatient Clinics
      3. 4.4.3 Rehabilitation Centers
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Medtronic (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Johnson & Johnson (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Abbott Laboratories (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Boston Scientific (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Stryker Corporation (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 B. Braun Melsungen AG (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Smith & Nephew (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Zimmer Biomet (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE OF SPINA BIFIDA
    3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 US MARKET ANALYSIS BY PATIENT AGE GROUP
    5. 6.5 US MARKET ANALYSIS BY HEALTHCARE SETTING
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY TYPE OF SPINA BIFIDA, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY TYPE OF SPINA BIFIDA, 2024 TO 2035 (USD Million)
    14. 6.14 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 CONSTRUCTION, BY PATIENT AGE GROUP, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million)
    18. 6.18 CONSTRUCTION, BY HEALTHCARE SETTING, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE OF SPINA BIFIDA, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million)
      4. 7.2.4 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Construction Market Segmentation

Construction By Type of Spina Bifida (USD Million, 2025-2035)

  • Spina Bifida Occulta
  • Meningocele
  • Myelomeningocele

Construction By Treatment Type (USD Million, 2025-2035)

  • Surgical Intervention
  • Medication
  • Physical Therapy
  • Occupational Therapy

Construction By Patient Age Group (USD Million, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

Construction By Healthcare Setting (USD Million, 2025-2035)

  • Hospitals
  • Outpatient Clinics
  • Rehabilitation Centers